Actovegin

Actovegin is a deproteinized hemodialysate of calf blood produced by ultrafiltration, retaining only low-molecular-weight bioactive constituents below approximately 5 kDa. The preparation contains more than 200 compounds including amino acids, oligopeptides, nucleosides, electrolytes, and trace elements. The pharmacologically most studied constituents are inositol phospho-oligosaccharides (IPOs), which exert insulin-mimetic effects by promoting translocation of glucose transporters GLUT1 and GLUT4 to the cell surface independently of insulin signaling, increasing intracellular glucose uptake and aerobic energy metabolism.

At the mitochondrial level, Actovegin enhances oxidative phosphorylation and augments ATP synthesis under ischemic or hypoxic conditions. A further mechanism is inhibition of poly(ADP-ribose) polymerase (PARP), whose overactivation during oxidative DNA damage drives cell death pathways relevant to both ischemic neuronal injury and diabetic polyneuropathy.

Actovegin also modulates the nuclear factor-kB (NF-kB) pathway, reducing pro-inflammatory cytokines including TNF-alpha while preserving regenerative inflammatory signaling. Anti-apoptotic effects include dose-dependent attenuation of caspase-3 activation induced by amyloid-beta peptides. Improvements in microcirculation — via increased capillary flow speed and reduced precapillary arteriolar smooth muscle tone — are also documented. Collectively, these pleiotropic actions converge on improved cellular energy balance, reduced oxidative stress, and decreased apoptosis in ischemia-vulnerable tissues.

The most robust evidence comes from three multicenter, randomized, double-blind, placebo-controlled trials. In a diabetic polyneuropathy trial (Ziegler et al., Diabetes Care, 2009; PMID 19470838; n=567), type 2 diabetic patients received 20 intravenous infusions of Actovegin 2,000 mg/day followed by 1,800 mg/day orally for 140 days. Total symptom score (TSS) improved significantly versus placebo (P=0.0003); vibration perception threshold fell approximately 5% (P=0.017); sensory neuropathy impairment scores and the SF-36 mental health domain also improved significantly. Adverse event incidence was similar between groups.

The ARTEMIDA trial (Guekht et al., Stroke, 2017; PMID 28432265; n=503) randomized post-stroke patients aged 60 or older at 33 hospitals in Russia, Belarus, and Kazakhstan. Actovegin 2,000 mg/day IV for up to 20 infusions was followed by 1,200 mg/day orally for a total six-month course. The primary endpoint (ADAS-cog+ change at six months) showed a statistically significant treatment difference of -2.3 points (95% CI -3.9 to -0.7; P=0.005) favoring Actovegin. New dementia diagnoses occurred in 7.3% versus 10.5% of patients at six months. A nonsignificant numerical excess of recurrent ischemic stroke was observed in the Actovegin arm (odds ratio 2.09).

The APOLLO phase IIIb trial (Suchkov et al., International Angiology, 2022; n=366) enrolled patients with Fontaine stage IIB peripheral arterial disease. Initial claudication distance increased 29.2% at 12 weeks (P=0.0041) and 35.5% at 24 weeks (P=0.0047) with Actovegin 1,200 mg/day (IV two weeks, then oral ten weeks), versus nonsignificant changes with placebo.

A 2022 PLOS ONE systematic review (la Fleur et al.) of five studies (3,879 total patients) rated four as low quality and one (ARTEMIDA) as moderate-high quality, concluding that evidence of benefit in stroke management remains uncertain and that a potential risk of harm cannot be excluded.

Typical dosage: 5-10 ml (multiple weekly).

The most rigorously documented regimens follow an intravenous loading phase followed by oral maintenance. In the diabetic polyneuropathy and post-stroke cognitive impairment trials, the IV phase consisted of 2,000 mg as a slow infusion once daily for 20 consecutive days. Oral maintenance in the diabetic neuropathy trial used 1,800 mg/day (200 mg tablets, three tablets three times daily before meals) for 140 days; in ARTEMIDA, oral maintenance was 1,200 mg/day for the remainder of a six-month total course.

• Diabetic polyneuropathy: 2,000 mg/day IV x 20 days, then 1,800 mg/day oral x 140 days • Post-stroke cognitive impairment: 2,000 mg/day IV x up to 20 infusions, then 1,200 mg/day oral x ~5 months • Peripheral arterial disease (APOLLO): 1,200 mg/day IV x 2 weeks, then 1,200 mg/day oral x 10 weeks • Intramuscular injection: up to 5 mL per injection for lower-volume indications in some approved-market formulations • Topical (wound healing): 20% cream or 20% gel applied once to several times daily per wound care protocol

Oral-only regimens reported in community and clinical settings outside trial protocols range from 600 to 1,800 mg/day in divided doses over four to six-week courses.

This information is drawn from published clinical trial protocols and prescribing information from jurisdictions where Actovegin holds marketing authorization. It is provided for educational reference only and does not constitute medical advice. Actovegin is not approved by the U.S. Food and Drug Administration or Health Canada.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In clinical practice in countries where Actovegin is registered, it is frequently prescribed alongside other neurometabolic agents, though formal controlled evidence for most combinations is absent. Concurrent use with alpha-lipoic acid in diabetic neuropathy management is common in Eastern European and German clinical settings; each agent has an independent randomized-trial evidence base for this indication, but no adequately powered RCT has directly evaluated the combination versus either monotherapy.

Actovegin is sometimes co-prescribed with Cerebrolysin, another animal-derived neurotrophic preparation, in post-stroke or neurodegenerative rehabilitation in Russia and the former Soviet Union. Evidence for this specific combination is primarily observational and should be regarded as anecdotal.

Pentoxifylline, which improves blood rheology by a distinct mechanism, is combined with Actovegin in some Eastern European vascular disease practices; no controlled trial data support this pairing, and this use is anecdotal. Combination with B vitamins in neuropathy rehabilitation reflects common clinical bundling rather than evidence for pharmacological synergy specific to Actovegin.

Actovegin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Rare allergic reactions

Across the major randomized clinical trials, Actovegin demonstrated a safety profile broadly comparable to placebo. The most clinically significant documented risk is hypersensitivity reaction. Urticaria, skin redness with burning sensation, drug-induced fever, and myalgia have been reported; at least one case of anaphylactic shock is documented in the literature. Approved-market prescribing information recommends a test injection before the first therapeutic dose. Mild and transient effects include gastrointestinal discomfort, nausea, headache, and dizziness. Injection site reactions including pain, redness, and local swelling can occur with intravenous and intramuscular administration.

A theoretical risk arises from the bovine origin of the preparation. Actovegin is manufactured by ultrafiltration retaining only components below approximately 5 kDa, a cutoff intended to exclude larger prion-related proteins. No cases of prion transmission attributable to Actovegin have been documented in the published scientific literature, and manufacturers report sourcing from BSE-controlled herds. Nonetheless, regulators in the United States and Canada have not approved the product, citing bovine-derived injectable concerns alongside insufficient efficacy demonstration by their standards.

Contraindications in approved prescribing information include known hypersensitivity to hemoderivative preparations, decompensated heart failure, and anuria or oliguria. The ARTEMIDA trial observed a nonsignificant numerical excess of recurrent ischemic stroke in the Actovegin arm (odds ratio 2.09), warranting caution in patients at elevated vascular risk.

Under WADA rules, Actovegin is not itself a prohibited substance, but intravenous infusions exceeding 100 mL per dose are prohibited under the general M2 intravenous infusion prohibition, which applies to the standard 2,000 mg IV dosing used in clinical protocols.